 WOODCLIFF LAKE, N.J.--BUSINESS WIRE--Eagle Pharmaceuticals, Inc. Nasdaq: EGRX Eagle or the Company today announced that the U.S. District Court for the District of Delaware held that Eagles proposed vasopressin product does not infringe any of the patents Par asserted against the Company. Eagle is first to file an Abbreviated New Drug Application ANDA referencing Vasostrict, which had total U.S. sales of 786 million in 2020. In May 2018, Par sued Eagle for infringement of sever 